• Dasatinib: A Phospho-Signaling Decision Guide

  2026-09-02

  Dasatinib (BMS-354825) is a powerful Src and Bcr-Abl inhibitor for dissecting kinase-dependent phenotypes. This guide connects its validated pharmacology with the SNAI1–PIK3R2/p-EphA2 findings in thymic epithelial tumors while emphasizing assay interpretation, model selection, and experimental limitations.

• Cyclophilin A Defines Cyclosporin Immunosuppression

  2026-09-01

  Colgan and colleagues used genetic deletion, ex vivo T-cell assays, in vivo allogeneic challenge, and adoptive reconstitution to test whether Cyclophilin A is required for cyclosporin-mediated immunosuppression. Their results show that CypA is the principal intracellular mediator of calcineurin inhibition and immune suppression by cyclosporin, providing a strong mechanistic basis for interpreting resistance phenotypes in experimental models.

• Metabolic Sensitization of Ferroptosis and Cuproptosis

  2026-09-01

  Zhang and colleagues developed a Cu–tannic acid/liposome nanosystem carrying STF-31 to inhibit glycolysis and compensatory NAD+ metabolism, thereby increasing tumor-cell susceptibility to ferroptosis and cuproptosis. The study links metabolic depletion with copper retention, redox failure, immunogenic cell death, and tumor immune remodeling, offering a mechanistic framework for combination nanomedicine design.

• PRMT6-Mediated Antiviral Immunity in Plants

  2026-08-31

  Zhu et al. identify protein arginine methyltransferase 6 (PRMT6) as a plant antiviral factor that disables the tomato bush stunt virus P19 silencing suppressor. The study connects PRMT6-dependent methylation at conserved P19 arginine residues with impaired dimerization and small-RNA binding, while natural PRMT6 expression alleles help explain variation in tomato resistance.

• Recent Advances in Ibuprofen and Naproxen Synthesis

  2026-08-31

  Ha and Paek’s review examines how ibuprofen and naproxen synthesis has evolved from established industrial routes toward more efficient, asymmetric, derivative-oriented, and continuous-flow strategies. Its main practical value is a framework for comparing step economy, stereochemical control, scalability, and route adaptability when preparing aryl-propionic acid NSAIDs.

• Rhodamine B for Nanomedicine Imaging Workflows

  2026-08-30

  Rhodamine B, also called Basic Violet 10, supports practical cell labeling, particle-tracking, and fluorescence-based assay workflows. This guide connects its use as a fluorescent reporter with a trypsin-responsive nanomedicine strategy for acute pancreatitis, while separating validated findings from assay-design recommendations.

• Trichostatin A for Organoid Epigenetic Studies

  2026-08-29

  Use Trichostatin A as a reversible chromatin perturbation tool to connect histone acetylation with organoid growth, differentiation, and cellular diversity. This workflow also positions TSA as a benchmark for cancer research, including breast cancer cell proliferation inhibition assays.

• Z-VDVAD-FMK in Caspase-2 Apoptosis Workflows

  2026-08-28

  Z-VDVAD-FMK provides a cell-permeable, irreversible way to interrogate caspase-2-linked apoptosis, mitochondrial signaling, and downstream caspase activity. Its value is greatest in orthogonal workflows that separate caspase-dependent rescue from caspase-independent cell death, including emerging host–virus studies.

• Cyclosporin A: Assays, Workflows, and Optimization

  2026-08-28

  Cyclosporin A provides a versatile way to connect cyclophilin-dependent signaling with calcineurin–NF-AT suppression and mitochondrial pore regulation. This practical guide shows how to design dose-response experiments, compare cyclosporin variants, and troubleshoot cell-based and mitochondrial assays.

• miR-24-3p/Sp1/PI3K Axis in Doxorubicin HF

  2026-08-27

  The reference study identifies miR-24-3p as a direct negative regulator of Sp1 and links this interaction to PI3K signaling, cardiomyocyte apoptosis, oxidative stress, and doxorubicin-induced heart failure. Its combined animal, cell, inhibitor, gene-manipulation, and dual-luciferase design provides a mechanistic framework for evaluating the miR-24-3p/Sp1/PI3K axis in cardiac injury research.

• TNF-alpha Recombinant Murine Protein for Apoptosis

  2026-08-27

  Use TNF-alpha recombinant murine protein as a defined extracellular trigger for apoptosis, inflammation, and receptor-signaling experiments. This workflow also shows how to pair tumor necrosis factor alpha treatment with RNA Pol II stress assays without confusing distinct cell-death mechanisms.

• FXR–KLF11 Signaling in Contrast-Induced AKI

  2026-08-26

  The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Using mouse and HK-2 cell models, the authors connect Chenodeoxycholic Acid-driven FXR activation with reduced tubular injury, inflammation, and apoptosis, while genetic and transcriptional experiments support pathway causality.

• Two Flavone 2′-Glucosides from Scutellaria

  2026-08-26

  The 1995 reference study isolated two previously undescribed 2′-O-glucosylated flavones from Scutellaria baicalensis roots and established their structures using chromatographic and spectroscopic evidence. It also re-isolated baicalin methyl ester among seven known phenolics, providing important phytochemical context for later studies of this esterified derivative of baicalin.

• Molidustat (BAY85-3934) HIF Assay Workflow

  2026-08-25

  Molidustat (BAY85-3934) enables controlled hypoxia-inducible factor stabilization without relying on hypoxic exposure alone. This workflow connects HIF-PH inhibition to cardiomyocyte stress assays, erythropoietin stimulation, and chronic kidney disease anemia research while emphasizing formulation control and pathway-specific validation.

• VZV gE Mutations Improve mRNA Vaccine Responses

  2026-08-25

  Cao and colleagues tested whether altering the carboxyl-terminal trafficking motifs of varicella-zoster virus glycoprotein E could improve the immunogenicity of an LNP-formulated mRNA vaccine. Their combined C-terminal mutant produced the most consistent humoral and cellular responses, providing a useful antigen-engineering strategy for future varicella-zoster vaccine development.

8062 records 1/538 page Next 12345 下5页 Last page